| Prev Close: | 28.70 |
|---|
| Open: | N/A |
|---|
| Bid: | 28.58 x 400 |
|---|
| Ask: | 28.65 x 300 |
|---|
| 1y Target Est: | 31.47 |
|---|
| Beta: | 0.81 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 21.40 - 31.15 |
|---|
| Volume: | 2,800 |
|---|
| Avg Vol (3m): | 32,369,000 |
|---|
| Market Cap: | 203.58B |
|---|
| P/E (ttm): | 13.74 |
|---|
| EPS (ttm): | 2.09 |
|---|
| Div & Yield: | 0.96 (3.30%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Johnson & Johnson Stock Checkup for Mayat Motley Fool(Tue 2:06AM EDT)
- Pfizer halts study of non-Hodgkin's lymphoma drugAP(Mon, May 20)
- ‘Love Hormone’ Promises Safer Births After Pfizer Flopat Bloomberg(Mon, May 20)
- Final Glance: Pharmaceuticals companiesAP(Mon, May 20)
- Pfizer halts study of lymphoma drug unlikely to help survivalat Reuters(Mon, May 20)
- Can Pfizer’s Love Hormone Cut Down Maternal Mortality?at Wall St. Cheat Sheet(Mon, May 20)
- InPlay: Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to FutilityBriefing.com(Mon, May 20)
- Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to FutilityBusiness Wire(Mon, May 20)
- WASIK COLUMN-Two ways to pick your summer stock retreatat Reuters(Mon, May 20)
- A New Drug Sales Modelat Motley Fool(Mon, May 20)
- Vitamins That Cost Pennies a Day Seen Delaying Dementiaat Bloomberg(Mon, May 20)
- 6 Healthy Products That Aren'tat Minyanville(Mon, May 20)
- The 3 Deadliest Diseases in the U.S.at Motley Fool(Mon, May 20)
- Midday Glance: Pharmaceuticals companiesAP(Mon, May 20)
- March 2014 Options Now Available For Pfizer (PFE)at Forbes(Mon, May 20)
Key Statistics
| Forward P/E (1 yr): | 12.21 |
|---|
| P/S (ttm): | 3.53 |
|---|
| Ex-Dividend Date: | 08-May-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.21 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.58 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | 4.75 |
|---|
Business Summary
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care phys...
View More